Selection of optimal treatment for massive to irreparable rotator cuff tears (RCTs) requires a challenging decision-making process in which surgeons must consider several factors, including duration of symptoms, tear pattern, tear size, and muscle quality. Patient characteristics such as age, comorbidities, shoulder dominance, and activity level also must be considered. Cofield et al^[@bibr12-2325967119875717]^ classified massive tears as those greater than 5 cm in anteroposterior length. Gerber et al^[@bibr24-2325967119875717]^ defined massive tears as those involving 2 or more rotator cuff tendons. Surgical repair of RCTs with these characteristics is often technically challenging and is associated with higher rates of treatment failure or only modest clinical improvement.^[@bibr1-2325967119875717],[@bibr12-2325967119875717]^ Rockwood et al^[@bibr43-2325967119875717]^ described irreparable RCTs as those in which a direct repair of the native tendon to its insertion site is not possible. Signs of irreparability include fatty infiltration affecting 50% or more of the rotator cuff musculature, static superior migration of the humeral head, and a narrowed or absent acromiohumeral interval on an upright anteroposterior shoulder radiograph.^[@bibr4-2325967119875717]^

Treatment for such tears spans a spectrum that includes nonoperative treatment; surgical options such as subacromial decompression, biceps tenotomy or tenodesis, tuberoplasty, partial RTC repair; and more extensive and complex procedures such as superior capsular reconstruction, tendon transfers, and reverse total shoulder arthroplasty (RTSA). Unfortunately, no clear consensus has been reached regarding optimal management. When nonoperative treatment fails, operative management is often indicated to reduce pain, restore shoulder function, and decrease likelihood of cuff tear arthropathy that can cause progressive destruction of the glenohumeral joint.^[@bibr15-2325967119875717]^

A relatively new treatment modality for patients with massive to irreparable RCTs is the InSpace (Orthospace) biodegradable balloon system. The balloon is composed of a polylactide and ∊-caprolactone copolymer that is believed to biodegrade within 12 months.^[@bibr10-2325967119875717],[@bibr33-2325967119875717],[@bibr45-2325967119875717]^ The procedure can be performed under general or local anesthesia, and the balloon is most commonly inserted arthroscopically though a lateral portal. The device is designed to serve as a physical barrier to reduce subacromial friction, and it aims to restore proper shoulder biomechanics by lowering the humeral head closer to its anatomic position against the glenoid cavity during dynamic movements.^[@bibr45-2325967119875717]^ The technique was described by Savarese and Romeo^[@bibr45-2325967119875717]^ in 2012, and the earliest results of clinical outcomes were published by Senekovic et al^[@bibr47-2325967119875717]^ in 2013. Subsequent studies have used the balloon, both alone and in combination with other procedures such as subacromial decompression, biceps tenotomy, acromioplasty, bursectomy, and partial tendon repair.^[@bibr52-2325967119875717]^

The purpose of this study was to critically review the literature reporting clinical outcomes of subacromial balloon spacer implantation for the treatment of massive and irreparable RCT. We hypothesized that postoperative clinical outcomes will demonstrate pain reduction and improved shoulder function.

Methods {#section1-2325967119875717}
=======

A systematic review of the literature was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines^[@bibr35-2325967119875717]^ to assess outcomes of subacromial balloon spacer implantation for massive and irreparable RCTs. This review was registered with the PROSPERO international prospective register of systematic reviews (PROSPERO registration identification: CRD42019123408).

Search Strategy {#section2-2325967119875717}
---------------

A comprehensive literature search was performed through use of the MEDLINE and Cochrane Library electronic databases. The following terms were used as keywords and appeared in the title, abstract, or keyword fields: (1) massive rotator cuff tear (n = 908); (2) irreparable rotator cuff tear (n = 464); (3) subacromial spacer (n = 30); subacromial balloon (n = 13); and balloon spacer (n = 40). The final search was performed on September 25, 2018.

Study Selection {#section3-2325967119875717}
---------------

Trials were eligible for inclusion if they met the following criteria: human participants with documented massive and/or irreparable RCTs, subacromial balloon spacer implantation, and patient outcome after at least 6 months of follow-up for clinical trials. Studies involving animals, cadaveric specimens, operative techniques, and partial RCT were excluded, as were duplicates and nonrelevant studies. Non--English language articles were excluded if direct translation was not possible. Study selection was determined by examining the title and/or abstract of all articles obtained from the database search. Full texts of these potentially relevant studies were then obtained and analyzed for eligibility. Additionally, all references within relevant studies were cross-referenced for inclusion if missed by the initial search. In cases of duplicate patient populations reported in separate studies, only the study with longer duration follow-up was retained for inclusion.

Data Extraction and Analysis {#section4-2325967119875717}
----------------------------

Data were collected and recorded in a Microsoft Excel spreadsheet (version 2016). Data regarding study design, level of evidence, sample size, patient age, patient sex, follow-up, indications, surgical techniques, rehabilitation protocols, and concomitant procedures performed were recorded. Studies were assessed for multiple outcomes of interest including the Constant score, Oxford Shoulder Score (OSS), University of California Los Angeles Shoulder Score, American Shoulder and Elbow Surgeons (ASES) score, and the abbreviated Disabilities of the Arm, Shoulder and Hand (QuickDASH) score, as well as complications, reoperation rates, and patient satisfaction.

Quality Assessment {#section5-2325967119875717}
------------------

The MINORS (Methodological Index for Non-Randomized Studies) checklist was used to assess the methodologic quality of included studies.^[@bibr50-2325967119875717]^ The checklist assigns a score of 0-2 for 8 items applicable to nonrandomized studies, with a maximum score of 16 indicating the highest possible score for an individual nonrandomized study. The items were scored 0 if not reported; 1 when reported but inadequate; and 2 when reported and adequate. A minimum of 18 months was deemed an appropriate length of follow-up, as the balloon spacer is believed to completely biodegrade within 12 months of insertion, thus allowing for assessment of primary endpoints and possible adverse effects. After thorough review of MINORS scoring guidelines, 2 authors (R.K.S., L.K.) independently reviewed and scored each included study. Any disagreements in scoring were resolved by consensus discussion with the senior author (B.R.W.). The κ (Fleiss) statistic was calculated to determine interrater reliability.

Statistical Analysis {#section6-2325967119875717}
--------------------

Statistical analysis was used to describe data and assess outcomes. Descriptive statistics were calculated from each included study, with continuous variables reported as means ± SDs and categorical variables reported as frequencies with percentages. As all of the studies included in this review were nonrandomized and they exhibited significant variation in study design, patient selection criteria, and concomitant procedures performed, pooling of outcome measures was not performed. Instead, the results are presented in narrative summary fashion.

Results {#section7-2325967119875717}
=======

Included Studies {#section8-2325967119875717}
----------------

The initial database search identified 1455 total studies. After application of the systematic screening strategy ([Figure 1](#fig1-2325967119875717){ref-type="fig"}), a total of 12 clinical studies were included in this review. Of these, 9 (69%) reported no conflicts of interest. The systematic screening approach did not yield any non--English language studies that directly examined clinical results in patients treated with the subacromial balloon spacer; thus, none were excluded solely on the basis of inaccessible direct translation into English.

![Literature selection process algorithm.](10.1177_2325967119875717-fig1){#fig1-2325967119875717}

Study Quality {#section9-2325967119875717}
-------------

The included studies were composed of 10 case series, 1 prospective cohort study, and 1 retrospective cohort study. All studies were nonrandomized. The median MINORS score was 9.5 of 16 ([Table 1](#table1-2325967119875717){ref-type="table"}). None of the studies used unbiased endpoint assessment, and no study prospectively calculated the target study size. Although 8 of the 12 studies (67%) had an appropriate mean follow-up time, only 3 of the 12 studies (25%) had a loss to follow-up rate less than 5%. In 2 studies, loss to follow-up rate could not be determined, as only patients with a minimum follow-up of 1 year were included. Substantial interrater reliability was noted in scoring between reviewers, with κ = 0.66.

###### 

Study Demographic Characteristics and Design*^a^*

![](10.1177_2325967119875717-table1)

  Lead Author (Year)                                Shoulders/Patients, n   Mean Age, y   Mean Follow-up, mo   Study Design (LOE)               MINORS Score
  ------------------------------------------------- ----------------------- ------------- -------------------- -------------------------------- --------------
  Naggar^[@bibr37-2325967119875717]^ (2016)         22/21                   69.3          52.5                 Prospective case series (4)      11/16
  Gervasi^[@bibr26-2325967119875717]^ (2016)        15/15                   74.6          20                   Prospective case series (4)      10/16
  Holschen^[@bibr27-2325967119875717]^ (2017)       12/12                   62.4          22.3                 Retrospective cohort study (3)   9/16
  Senekovic^[@bibr46-2325967119875717]^ (2017)      20/20                   68.8          49                   Prospective case series (4)      10/16
  Basat^[@bibr3-2325967119875717]^ (2017)           12/12                   64.3          38.3                 Prospective case series (4)      11/16
  Deranlot^[@bibr13-2325967119875717]^ (2017)       39/37                   69.8          32.8                 Retrospective case series (4)    9/16
  Ricci^[@bibr42-2325967119875717]^ (2017)          30/30                   65.7          9.8                  Retrospective case series (4)    8/16
  Piekaar^[@bibr39-2325967119875717]^ (2018)        46/44                   66            12                   Prospective case series (4)      9/16
  Maman^[@bibr34-2325967119875717]^ (2017)          42/42                   ---           12                   Prospective cohort study (3)     9/16
  Prat^[@bibr41-2325967119875717]^ (2018)           24/22                   70.7          14.4                 Retrospective case series (4)    9/16
  Yallapragada^[@bibr54-2325967119875717]^ (2018)   14/14                   76.2          12.6                 Prospective case series (4)      9/16
  Ruiz Ibán^[@bibr44-2325967119875717]^ (2018)      15/15                   69.4          24                   Prospective case series (4)      11/16

*^a^*Dash (---) indicates that value was not reported. LOE, level of evidence; MINORS, Methodological Index for Non-Randomized Studies.

Patient Characteristics {#section10-2325967119875717}
-----------------------

The 12 studies reporting clinical outcomes, all with level 3 or 4 evidence, were included for data extraction and analysis. In total, 291 shoulders (in 284 patients) undergoing subacromial balloon spacer implantation were studied from all included articles. Patient age and sex were reported for 242 patients (85.2%; 11 studies), yielding a mean age of 68.5 ± 4.2 years (range, 62.4-76.2 years) and slight male predominance (51.2%). The mean duration of follow-up was 22.9 ± 14.9 months (range, 6-60 months) ([Table 1](#table1-2325967119875717){ref-type="table"}).

Surgical Methods and Rehabilitation Protocol {#section11-2325967119875717}
--------------------------------------------

In all studies, devices were implanted with the patient in either the beach-chair or lateral decubitus position. Standard arthroscopic portals were used for device deployment, with the exception of 1 case that was converted to a mini-open approach.^[@bibr46-2325967119875717]^ Device deployment time was assessed in 2 studies, each with a mean time of 10 minutes (range, 2-30 minutes). One additional study reported a mean operation time (including diagnostic arthroscopy and concomitant procedures) of 33 minutes.^[@bibr3-2325967119875717]^ Preoperative tear characteristics and concomitant procedures are reported in [Table 2](#table2-2325967119875717){ref-type="table"}. Within the included studies, the use of a shoulder sling ranged from 1 to 3 weeks postoperatively. Active range of motion exercises were initiated between postoperative day 1 and postoperative week 3.

###### 

Study Features and Surgical Methods*^a^*

![](10.1177_2325967119875717-table2)

  Lead Author (Year)                                Tear Characteristics                                                                                                                             Exclusion Criteria*^b^*                                                                                           Anesthesia                  Concomitant Procedures
  ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------- --------------------------- --------------------------------------------------------------------------------------------------------------------------------
  Naggar^[@bibr37-2325967119875717]^ (2016)         Massive irreparable RCT                                                                                                                          CTA; complete insufficiency of external rotators                                                                  NA                          NA
  Gervasi^[@bibr26-2325967119875717]^ (2016)        Massive RCT; all with at least Goutallier stage 3 fatty infiltration                                                                             Significant glenohumeral instability; significant OA                                                              Local only                  NA
  Holschen^[@bibr27-2325967119875717]^ (2017)       Massive RCT                                                                                                                                      Shoulder OA; CTA with Hamada grade ≥3                                                                             General                     Balloon implanted "on top" of debridement (8 patients) or partial reconstruction (4 patients)
  Senekovic^[@bibr46-2325967119875717]^ (2017)      Larger than 5-cm tear involving at least supraspinatus and often involving infraspinatus, with fatty infiltration deemed unsuitable for repair   Significant OA; glenohumeral instability; prior shoulder surgery; DM; coagulopathy immunosuppression              General                     Isolated balloon implantation or 11 patients with concomitant LHB tenotomy
  Basat^[@bibr3-2325967119875717]^ (2017)           Larger than 5-cm tear with tendon retraction to glenoid level and stage 4 Goutallier fatty degeneration                                          CTA; neurologic deficit in the shoulder                                                                           General                     LHB tenotomy if present
  Deranlot^[@bibr13-2325967119875717]^ (2017)       Irreparable massive RCT confirmed with ultrasonography or MRI and reconfirmed during arthroscopy                                                 CTA with Hamada grade ≥3; subscapularis tear                                                                      General                     Subacromial debridement and LHB tenotomy for all patients (if tendon was previously intact)
  Ricci^[@bibr42-2325967119875717]^ (2017)          Massive irreparable RCT                                                                                                                          Shoulder OA; glenohumeral instability; prior shoulder surgery                                                     General                     LHB tenotomy, bursectomy, acromioplasty
  Piekaar^[@bibr39-2325967119875717]^ (2018)        Irreparable massive RCT confirmed with ultrasonography or MRI and reconfirmed during arthroscopy                                                 Severe shoulder OA; subscapularis tear; prior participation in study involving affected shoulder                  23 general; 21 local only   Debridement, bursectomy; LHB tenotomy if still intact; partial repair in 11 shoulders; distal clavicle resection in 1 shoulder
  Maman^[@bibr34-2325967119875717]^ (2017)          Massive irreparable RCT                                                                                                                          Shoulder OA; glenohumeral instability; prior shoulder surgery; uncontrolled DM; immunosuppression; coagulopathy   General                     21 patients underwent isolated debridement and balloon implantation; 21 patients underwent concomitant LHB tenotomy
  Prat^[@bibr41-2325967119875717]^ (2018)           Symptomatic irreparable RCT                                                                                                                      Inflammatory arthropathy; shoulder OA                                                                             General                     Debridement, bursectomy, LHB tenotomy
  Yallapragada^[@bibr54-2325967119875717]^ (2018)   Muscle retraction (higher than Patte stage 2); muscle atrophy, fatty degeneration (Goutallier stage 3)                                           CTA with Hamada grade ≥3; absence of preserved passive shoulder range of motion                                   NA                          All patients bursal decompression; 9/14 patients LHB tenotomy
  Ruiz Ibán^[@bibr44-2325967119875717]^ (2018)      Complete supraspinatus tears with at least partial tear of infraspinatus, as well as fatty infiltration \>50%                                    CTA with Visotsky-Seebauer type ≥2A; OA with Samilson-Prieto type ≥2                                              General                     Subacromial debridement, bursectomy, biceps LHB tenotomy if present

*^a^*CTA, cuff tear arthropathy; DM, diabetes mellitus; LHB, long head of the biceps; MRI, magnetic resonance imaging; NA, not applicable; OA, osteoarthritis; RCT, rotator cuff tear.

*^b^*Patients with active infection and device material allergy were excluded from all studies.

Patient Outcome Measures {#section12-2325967119875717}
------------------------

Several functional outcome measures were reported in the included studies, with all 12 studies including at least 1 of the following: Constant score, OSS, ASES score, or short version of the DASH score (QuickDASH) ([Table 3](#table3-2325967119875717){ref-type="table"}). The Constant score was the most frequently used outcome metric (11/12 studies), with improvements in mean Constant score ranging from 18.5 to 49.6 points.

###### 

Outcome Measures After Intervention*^a^*

![](10.1177_2325967119875717-table3)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    Constant Score*^b^*   OSS*^b^*             Patient Satisfaction, %*^c^*   Other               
  ------------------------------------------------- --------------------- -------------------- ------------------------------ ------------ ------ ----------------------------------------------------
  Naggar^[@bibr37-2325967119875717]^ (2016)         35.5                  72.3                 ---                            ---          ---    Final follow-up UCLA Shoulder Score: 29.8

  Gervasi^[@bibr26-2325967119875717]^ (2016)        31.9                  69.9                 ---                            ---          86.7   Final follow-up ASES score: 72.5 ± 23.5

  Holschen^[@bibr27-2325967119875717]^ (2017)       36.8                  69.5                 ---                            ---          91.7   Final follow-up ASES score: 85.7

  Senekovic^[@bibr46-2325967119875717]^ (2017)      36.4 ± 13.1           63.9 ± 20.5          ---                            ---          ---    ---

  Basat^[@bibr3-2325967119875717]^ (2017)           25.8 ± 5.3            75.4 ± 6.1           21.3 ± 5.3                     42.9 ± 2.9   100    ---

  Deranlot^[@bibr13-2325967119875717]^ (2017)       39 ± 15.2             64 ± 17.1            ---                            ---          ---    ---

  Ricci^[@bibr42-2325967119875717]^ (2017)          41                    64.4                 ---                            ---          ---    VAS pain (preoperative/final follow-up): 6.38/2.84

  Piekaar^[@bibr39-2325967119875717]^ (2018)        37.1 ± 15.9           60.2 ± 23.2          21.8 ± 7.7                     32.4 ± 11    79.5   VAS pain (preoperative/final follow-up): 6.84/3.27

  Maman^[@bibr34-2325967119875717]^ (2017)          36                    65.8                 ---                            ---          ---    ---

  Prat^[@bibr41-2325967119875717]^ (2018)           ---                   ---                  ---                            ---          45.8   Final follow-up UCLA shoulder score: 15.9 ± 6.87\
                                                                                                                                                  Final follow-up QuickDASH: 62.4 ± 28

  Yallapragada^[@bibr54-2325967119875717]^ (2018)   22.5 ± 5.2            51.4 ± 7.8           26 ± 1.8                       48.2 ± 5.8   ---    ---

  Ruiz Ibán^[@bibr44-2325967119875717]^ (2018)      35 \[25.5\]*^d^*      53.5 \[30.8\]*^d^*   ---                            ---          ---    Final follow-up QuickDASH: 27.5 \[12.3\]*^d^*
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*^a^*Values are presented as mean ± SD (if reported), unless otherwise noted. Dashes (---) indicate that values were not reported. ASES, American Shoulder and Elbow Surgeons; OSS, Oxford Shoulder Score; QuickDASH, short version of Disabilities of the Arm, Shoulder and Hand questionnaire; UCLA, University of California Los Angeles; VAS, visual analog scale.

*^b^*Only endpoints recorded at a minimum final follow-up of 6 months are included in outcome analysis.

*^c^*Percentage of patients satisfied or very satisfied with treatment outcome.

*^d^*Median value \[interquartile range\].

Constant subscale scores were reported in 5 studies (145 shoulders). Improvements in pain, activities of daily living (ADL), range of motion, and strength ([Figure 2](#fig2-2325967119875717){ref-type="fig"}) were observed in all 5 studies. In 2 studies,^[@bibr34-2325967119875717],[@bibr42-2325967119875717]^ strength was not statistically significant. In 1 study,^[@bibr37-2325967119875717]^ statistical significance was not reported for any subscale value. Among studies that assessed patient satisfaction (5 studies; 105 patients), rates of patients indicating they were satisfied or very satisfied with their treatment outcome ranged from 45.8% to 100%.

![Comparison of Constant (CS) subscale scores, preoperatively to final follow-up. ADL, activities of daily living; ROM, range of motion.](10.1177_2325967119875717-fig2){#fig2-2325967119875717}

We found that 5 studies assessed changes in active shoulder range of motion after subacromial balloon spacer implantation (104 patients). As well, 4 studies observed increases in active abduction; however, results from 1 of these studies were not statistically significant.^[@bibr44-2325967119875717]^ Of the 3 studies that reported active anterior elevation, all observed increases; however, only the results from 1 study were statistically significant (*P* = .00000001).^[@bibr54-2325967119875717]^ Similarly, although all 4 studies that assessed external rotation observed increased measurements at final follow-up, results from only 2 of these studies^[@bibr13-2325967119875717],[@bibr54-2325967119875717]^ were statistically significant (*P* = .001 and .0001, respectively).

Complications occurred in 2.1% of patients. These complications included transient neurapraxia of the lateral antebrachial cutaneous nerve in 1 patient, superficial wound infection in 1 patient, deep wound infection in 1 patient, and balloon migration in 3 patients. Of these, 3 patients (2 balloon migration, 1 deep wound infection) required subsequent surgeries for balloon removal. Balloon position was noted in 2 of the 3 cases of balloon migration, with both reporting anterior migration.

The included studies cited a dropout rate of 24 total patients. The reasons for patient dropout are shown in [Table 4](#table4-2325967119875717){ref-type="table"}. Of note, 2 studies^[@bibr13-2325967119875717],[@bibr54-2325967119875717]^ included results only for patients who met an inclusion criterion of minimum 1-year follow-up. The number of patients lost to follow-up prior to 1 year postoperatively was not reported.

###### 

Patient Dropout

![](10.1177_2325967119875717-table4)

  Reason for Dropout                                  n
  --------------------------------------------------- ----
  Conversion to reverse total shoulder arthroplasty   8
  Lost to follow-up                                   7
  Died from unrelated causes                          3
  Did not comply with study protocol                  4
  Withdrew consent                                    1
  Repeat arthroscopy prior to final follow-up         1
  Total patient dropout                               24

Discussion {#section13-2325967119875717}
==========

We found considerable heterogeneity among the studies reviewed, with significant variations in study design, patient selection criteria, and concomitant procedures performed ([Tables 2](#table2-2325967119875717){ref-type="table"} and [3](#table3-2325967119875717){ref-type="table"}). Results from the currently available literature showed generally positive clinical outcomes, with balloon implantation demonstrating effectiveness in pain reduction and functional improvement for patients with massive and irreparable RCTs ([Table 3](#table3-2325967119875717){ref-type="table"}). All 11 studies that used the Constant score as an outcome metric reported improvements in the mean score after balloon implantation (range of mean improvement, 18.5-49.6 points). Across the included studies, device implantation appeared to be a safe and reproducible procedure with a relatively low risk of complication (2.1%). RTSA was the most commonly cited salvage procedure, with 7 patients successfully converted to RTSA by final follow-up. This finding indicates that when balloon implantation fails, RTSA is a viable salvage option. Although the observed merits of this procedure are promising, the limitations of the included studies must be considered when these findings are applied to clinical practice.

Management of massive and irreparable RCTs remains a considerable challenge; a variety of treatments are offered, but we have no clear gold standard or definitive guidelines for optimal management. Proper patient selection is especially important in regard to treatment algorithms.^[@bibr25-2325967119875717],[@bibr38-2325967119875717]^ Compared with other, less complex treatment options such as arthroscopic debridement, subacromial decompression, and biceps tenotomy, the subacromial balloon spacer has demonstrated promising results on limited follow-up. Boileau et al^[@bibr6-2325967119875717]^ reported the results of 72 shoulders with massive and irreparable RCTs treated with either isolated biceps tenotomy or tenodesis. At mean final follow-up of 35 months, mean Constant scores increased by a mean of 20.2 points from 46.3 to 66.5 with no significant difference between groups. König and Braunstein^[@bibr31-2325967119875717]^ reported outcomes for 57 massive RCTs treated with arthroscopic debridement at short-term (2-4 years), midterm (5-6 years), and long-term (8-10 years) follow-up. Although outcomes showed substantial improvement in the short term (mean Constant score, 70.0), scores decreased to 51.0 and 42.3 at mid- and long-term follow-up, respectively. This trend demonstrates the limitations of many current options for palliative management of irreparable RCTs.

When compared with other minimally invasive, palliative treatment techniques such as subacromial decompression, biceps tenotomy or tenodesis, acromioplasty, and tuberoplasty, an important point of distinction with the subacromial balloon spacer system is that it more directly seeks to improve impaired shoulder biomechanics. Singh^[@bibr48-2325967119875717]^ performed a biomechanical study in 8 matched pairs of cadaveric shoulders to assess superior humeral head migration and functional abduction forces before and after implantation of a subacromial balloon. Initial testing of the intact shoulder state was performed to establish a baseline for each specimen. A 5-cm posterosuperior full-thickness tear involving both the supraspinatus and infraspinatus tendons was then created, and specimens were retested in the "torn state." As expected, shoulders in the torn state experienced a significant decrease in functional abduction force (*P* = .009). When specimens were tested after balloon insertion, functional abduction forces were restored to values comparable with the intact state. Compared with the torn state, the subacromial balloon spacer was able to significantly lower the humeral head by a mean of 2.8 ± 1.9 mm at all abduction angles and deltoid loads (*P* = .006).

Other, less complex procedures, such as tuberoplasty and acromioplasty, have sought to improve shoulder biomechanics through reduced friction at the narrowed acromiohumeral interval.^[@bibr20-2325967119875717],[@bibr32-2325967119875717]^ However, recent studies have reported that these techniques may actually increase anterosuperior humeral translation and may thus contribute to shoulder instability in some patients.^[@bibr9-2325967119875717],[@bibr51-2325967119875717]^ For this reason, simple debridement and biceps treatments have largely supplanted acromioplasty and tuberoplasty when a minimally invasive, palliative technique is preferred; however, these techniques are primarily palliative, with little expected biomechanical benefit. Conversely, the balloon may offer an option of similar invasiveness and complexity that more directly seeks to improve impaired shoulder biomechanics in the patient with rotator cuff deficiency.

Although the subacromial balloon seeks to improve shoulder biomechanics, it does not directly correct the underlying problem---the rupture of rotator cuff tendons. As such, functional improvements cannot be expected to match outcomes after rotator cuff repair, reconstructive techniques, or shoulder arthroplasty. RTSA has been increasingly used for irreparable RCTs with and without glenohumeral osteoarthritis. Ernstbrunner et al^[@bibr17-2325967119875717]^ performed a systematic review that included 8 studies with a minimum of level 4 evidence and at least 5 years of follow-up to examine long-term results of RTSA for rotator cuff dysfunction. Mean absolute Constant scores improved significantly from a mean score of 24 preoperatively to a mean score of 59 at last follow-up, with significant improvements in active anterior elevation and abduction and no deterioration in active range of motion up to 20 years after the operation. Although similar superior outcomes after RTSA have been well-documented,^[@bibr7-2325967119875717],[@bibr11-2325967119875717],[@bibr36-2325967119875717],[@bibr49-2325967119875717]^ it is an extensive and technically complex surgery associated with relatively high complication rates and limited salvage options, especially among younger patients with high-demand jobs and activities.^[@bibr2-2325967119875717],[@bibr36-2325967119875717],[@bibr56-2325967119875717]^ Favard et al^[@bibr19-2325967119875717]^ reported a complication rate of 18%, and Ernstbrunner et al^[@bibr18-2325967119875717]^ found complication rates as high as 39% in patient cohorts younger than 60 years.

Latissimus dorsi transfer is a treatment option for irreparable RCTs among relatively young patients without glenohumeral osteoarthritis or subscapularis insufficiency. El-Azab et al^[@bibr16-2325967119875717]^ reported outcomes of 115 shoulders with irreparable RCT treated with latissimus dorsi transfer after a mean follow-up of 9.3 years. The authors found significant improvements in pain level and shoulder function, including a sustained increase in Constant score from 44 preoperatively to 71 at final follow-up. However, the procedure requires a long rehabilitation process, and high rates of tendon rupture have been reported in the literature.^[@bibr29-2325967119875717]^ Superior capsular reconstruction is a relatively new technique for treatment of irreparable RCTs. Although its indications continue to evolve, early outcomes are promising on short-term follow-up. As with RTSA and latissimus dorsi transfer however, superior capsular reconstruction is a technically challenging procedure that requires prolonged surgical time and a substantial rehabilitation period.^[@bibr21-2325967119875717]^

Beyond a shared indication of massive to irreparable RCT, the included studies exhibited variability in patient selection that likely affected reported outcomes. We found that 2 studies in this review included a total of 6 shoulders with preoperative pseudoparalysis.^[@bibr27-2325967119875717],[@bibr44-2325967119875717]^ Postoperative shoulder function remained poor in all cases, with 2 shoulders converted to RTSA by final follow-up. Variable definitions for pseudoparalysis have been reported in the literature, further complicating management decisions in these cases.^[@bibr53-2325967119875717]^ Because of poor early outcomes and limited data, balloon spacer implantation in shoulders with pseudoparalytic characteristics cannot be recommended at this time.

The included studies also demonstrated variability in patient selection regarding the role of partial repair in shoulders treated with the balloon spacer system. We found that 2 studies in this review included a total of 15 patients in whom some degree of partial repair was performed in addition to balloon spacer insertion. Subgroup analysis in one of the studies showed no statistical difference between outcomes of shoulders treated with balloon insertion alone compared with those treated with concomitant partial repair.^[@bibr39-2325967119875717]^ The other study did not report subgroup analysis.^[@bibr27-2325967119875717]^ Limited reporting and sample sizes in these studies restrict the utility of the findings, but several studies have shown that partial repair of a massive RCT is generally recommended if some degree of repair is possible.^[@bibr5-2325967119875717],[@bibr23-2325967119875717],[@bibr28-2325967119875717],[@bibr30-2325967119875717],[@bibr38-2325967119875717],[@bibr40-2325967119875717]^ The implantation of the balloon laid on top of a partial repair may protect fragile repairs from subacromial friction while supporting the forces exerted by the partially repaired tendon^[@bibr8-2325967119875717],[@bibr52-2325967119875717]^; however, further studies are needed to fully investigate this potential benefit.

Prior studies have demonstrated that patients with medical comorbidities tend to experience less improvement after both surgical and nonsurgical treatment.^[@bibr22-2325967119875717]^ Furthermore, in patients treated with primary rotator cuff repair, rates of retear are higher in patients older than 50 years. In a retrospective cohort study of 1600 patients who had undergone arthroscopic rotator cuff repair, Diebold et al^[@bibr14-2325967119875717]^ found retear rates of 10% in patients aged 50 to 59 years, 15% in those aged 60 to 69 years, 25% in those aged 70 to 79 years, and 34% in those 80 years or older. These rates are substantially higher than the 5% retear rate that was seen in patients younger than 50 years. In addition to age, several patient factors such as diabetes, chronic vascular disease, and smoking have potential to alter the wound-healing process.^[@bibr55-2325967119875717]^ This topic has generated great interest in biological augmentation with platelet concentrates and cell-based therapies after rotator cuff repair; however, little evidence is available to show that these strategies can help in the setting of the muscle atrophy, retraction, and fatty infiltration that are characteristic of chronic RCTs. For patients with massive to irreparable RCT and poor wound healing parameters, the balloon spacer may be a beneficial therapy that does not rely heavily on tissue healing processes.

This systematic review revealed that the beneficial effects of the subacromial balloon system may persist beyond the time of device deflation and degradation, although the exact reason for this effect remains unclear. The balloon copolymers (polylactide and ∊-caprolactone) are believed to biodegrade within 12 months.^[@bibr10-2325967119875717],[@bibr33-2325967119875717],[@bibr45-2325967119875717]^ Of the studies included in this review, 6 studies reported varying degrees of postoperative radiographic findings. Ricci et al^[@bibr42-2325967119875717]^ found that balloons progressively decreased in size from 6 to 12 months postoperatively, and the investigators observed complete degradation in all patients assessed by magnetic resonance imaging at final follow-up of 24 months. Using ultrasonography, Senekovic et al^[@bibr46-2325967119875717]^ found that 86% of balloons were inflated at 3-month follow-up, but the devices were detectable in only 54.5% of patients at 6 months. Despite this, shoulder function and pain level demonstrated continued improvement in the majority of patients. In another included study, repeat arthroscopy was performed in 1 patient at 7 months and showed near-complete balloon degradation.^[@bibr39-2325967119875717]^ Holschen et al^[@bibr27-2325967119875717]^ reported results for 1 patient examined by magnetic resonance imaging after 12 months. Findings showed remnants of the deflated balloon with formation of scar tissue in the subacromial space. Although continued improvement in outcomes appears to be consistent across studies, further investigations are needed to fully elucidate the mechanisms underlying these findings.

Limitations {#section14-2325967119875717}
-----------

As with any systematic review, this study has several potential limitations that warrant discussion. The primary limitation relates to the methodological quality of the included clinical studies, all of which were nonrandomized observational studies. The lack of randomization and control groups, as well as variations in exclusion criteria, could have introduced selection bias into the results. Additionally, because of the heterogeneity of the reported data, included studies varied in the degree of detail offered regarding presurgical RCT characteristics, concomitant procedures performed, and outcome measures reported. Therefore, the potential for confounding cannot be discounted. Furthermore, most of the included articles were of level 4 evidence, with modest sample size and limited follow-up.

Conclusion {#section15-2325967119875717}
==========

This systematic review of the existing literature suggests that subacromial balloon spacer placement is a minimally invasive, technically simple procedure with low rates of perioperative complications and favorable patient-reported outcomes at limited short-term follow-up. This emerging technology may be most appropriately indicated for lower demand patients with or without advanced medical comorbidities in whom complete repair or more prolonged rehabilitation is not feasible. The inherent methodological limitations and patient heterogeneity between the studies we reviewed may have impaired our ability to fully characterize the longer term efficacy, particularly relative to other potential surgical options. Further prospective randomized or comparative studies are warranted to ascertain clinical outcomes of subacromial balloon spacer in the management of massive and irreparable RCTs.
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